the value and subsequent reimbursement of new and existing drugs, as well as reforms to obtain low prices for generic …

lead to an increased use of SCT and an increased number of quitters versus no reimbursement. Objective: To assess whether … reimbursement for SCT is a cost-effective intervention (from the Dutch societal perspective), we calculated the incremental costs … per quitter and extrapolated this outcome to incremental costs per QALY saved versus no reimbursement. Methods: In the …

pharmaceutical companies to submit the results of an economic evaluation when demanding reimbursement of new pharmaceuticals. The …

companies have evolved from supporting efforts to gain reimbursement on government drug plans to include pricing, promotion …

Background:Background: In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost … evidence and the decision-making process about drug reimbursement. Abstract: Aim:Aim: This study reviewed the methodological … Health Care Insurance Board (CVZ). The Board's newsletters provided information on the advice to, and reimbursement decisions …

inference in presenting evidence, and (ii) summarize evidence of cost effectiveness to inform societal reimbursement decisions … evidence across multiple strategies can be best presented and summarized to inform inference and societal reimbursement … made for best presenting and summarizing cost-effectiveness evidence for reimbursement decisions when comparing multiple …

Reimbursement Committee (DRC) evaluates reimbursement requests for orphan drugs based on multiple criteria: the therapeutic value …, price and proposed reimbursement tariff; the importance of the drug in clinical practice; and the budget impact of the drug …. Objectives: This study aimed to assess reimbursement dossiers of orphan drugs in Belgium and to compare them with the clinical …